EIP Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EIP Pharma, Inc.
EIP And Diffusion Combine To Form CNS Firm With Dementia Focus
The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.
Sanofi Looks To Atomwise For More AI Help
Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.
Roche Shelves Phase III Huntington's Candidate Tominersen
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
Roche Confident But Cautious On Alzheimer's Hopeful
The Swiss major has highlighted two high-risk, high-reward neurodegenerative programs that could be transformative for the treatment of Alzheimer's and Huntington's disease.
- Other Names / Subsidiaries
- EIP Pharma, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.